GeneDx Holdings Corp.
Close on Oct 19, 2026
- Market cap
- $1.97B
- P/E (TTM)
- –
- Dividend yield
- –
About GeneDx
Services-Health Services, SIC 8000
GeneDx Holdings Corp. operates as a genomics and diagnostics company focused on genetic testing services and solutions. Its offerings include diagnostic test products and diagnostic testing kits and materials, alongside technology rights and related services. The company categorizes its business operations under the GeneDx segment as well as an all other segments classification, serving third-party insurance payors, institutional customers, and self-pay individuals.
The company maintains operational activities across domestic and international locations, including operations or jurisdictions in California, Florida, Maryland, North Carolina, Pennsylvania, Canada, and Iceland. GeneDx Holdings Corp. is headquartered in Stamford, Connecticut, with its principal executive offices located at 333 Ludlow Street.
Summary of the business section of GeneDx's latest annual report, written by StockData.
Company profile
Company
- Legal name
- GeneDx Holdings Corp.
- Headquarters
- Stamford, CT
- Address
- 333 Ludlow Street, North Tower, 6th Floor 06902
- Phone
- (888) 729-1206
- Website
- genedx.com
- Employees
- 1,300, Dec 31, 2025
- Industry
- Services-Health Services
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- ERNST & YOUNG LLP, New York, New York
Stock & identifiers
- Ticker
- WGS
- Exchange
- Nasdaq
- IPO date
- Sep 3, 2020
- Shares outstanding
- 30M, Jul 27, 2026
- Public float
- $1.66B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-33 reverse, May 4, 2023; 1-for-33 reverse, May 4, 2023
- SEC CIK
- 1818331
- CUSIP
- 81663L200
- ISIN
- US81663L2007
- EIN
- 85-1966622
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Katherine Stueland | CHIEF EXECUTIVE OFFICER, Director | 115,476 |
| Kevin Feeley | CHIEF FINANCIAL OFFICER | 48,035 |
| Mark A. Gardner | President | – |
| Bryan Dechairo | Chief Operating Officer | 2,723 |
| Thomas Fuchs | Director | 1,146 |
| Emily M. Leproust | Director | 24,852 |
| Keith A. Meister | Director | 4,808,275 |
| Joshua Ruch | Director | 189,566 |
| Richard C. Pfenniger Jr | Director | 45,082 |
| Eli Casdin | Director | 4,083,648 |
| Jason Ryan | Director | 118,764 |
| Casdin Partners GP, LLC | Director | – |
| Casdin Partners Master Fund, L.P. | Director | 3,880,072 |
| Casdin Capital, LLC | Director | 3,859,555 |
| Management LP Corvex | Director | 3,374,334 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Katherine Stueland | $13.55M | $43.35M | $4.14M | $1494 | $139 |
| FY2024 Katherine Stueland | $4.42M | $51.51M | $895.54K | $883 | $104 |
| FY2023 Katherine Stueland | $3.50M | $545.95K | $1.24M | $32 | $105 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“Our team of nearly 1,300 individuals are champions of not only our organization, but our patients, providers and partners.”
Corporate history
Events identified from SEC filings